Literature DB >> 9106740

Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra.

E D French1, K Dillon, X Wu.   

Abstract

Extracellular recordings were used to determine the effects of cannabinoids on the activity of dopamine neurons within the ventral tegmental area (VTA) and substantia nigra pars compacta (SNC). Systemic administration of the natural psychoactive cannabinoid delta 9-tetrahydrocannabinol (delta 9-THC) and the synthetic cannabimimetic aminoalkylindole WIN 55,212-2 produced dose-dependent increases in firing rate and burst firing in both neuronal populations. These effects appear to be specific as the non-psychoactive cannabidiol and the inactive enantiomer WIN 55,212-3 failed to alter either parameter of neuronal excitability. Furthermore, dopamine neurons in the VTA were more sensitive than those in the SNC to the stimulatory actions of delta 9-THC. These results may provide a mechanism by which psychoactive cannabinoids increase extracellular dopamine levels in mesolimbic and striatal tissues, and thereby contribute to the reinforcing effects of marijuana.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9106740     DOI: 10.1097/00001756-199702100-00014

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  101 in total

1.  Inhibitory inputs from rostromedial tegmental neurons regulate spontaneous activity of midbrain dopamine cells and their responses to drugs of abuse.

Authors:  Salvatore Lecca; Miriam Melis; Antonio Luchicchi; Anna Lisa Muntoni; Marco Pistis
Journal:  Neuropsychopharmacology       Date:  2011-12-14       Impact factor: 7.853

Review 2.  Endocannabinoids and exercise.

Authors:  A Dietrich; W F McDaniel
Journal:  Br J Sports Med       Date:  2004-10       Impact factor: 13.800

3.  Sensorimotor gating in mice is disrupted after AM404, an anandamide reuptake and degradation inhibitor.

Authors:  Emilio Fernandez-Espejo; Beatriz Galan-Rodriguez
Journal:  Psychopharmacology (Berl)       Date:  2004-04-16       Impact factor: 4.530

Review 4.  Adenosine-cannabinoid receptor interactions. Implications for striatal function.

Authors:  Sergi Ferré; Carme Lluís; Zuzana Justinova; César Quiroz; Marco Orru; Gemma Navarro; Enric I Canela; Rafael Franco; Steven R Goldberg
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

5.  Genetic Versus Pharmacological Assessment of the Role of Cannabinoid Type 2 Receptors in Alcohol Reward-Related Behaviors.

Authors:  Matthew S Powers; Kristen R Breit; Julia A Chester
Journal:  Alcohol Clin Exp Res       Date:  2015-12       Impact factor: 3.455

6.  Dopaminergic augmentation of delta-9-tetrahydrocannabinol (THC) discrimination: possible involvement of D(2)-induced formation of anandamide.

Authors:  Marcello Solinas; Gianluigi Tanda; Carrie E Wertheim; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2010-02-24       Impact factor: 4.530

7.  The endocannabinoid system modulates the valence of the emotion associated to food ingestion.

Authors:  Mónica Méndez-Díaz; Pavel Ernesto Rueda-Orozco; Alejandra Evelyn Ruiz-Contreras; Oscar Prospéro-García
Journal:  Addict Biol       Date:  2010-12-23       Impact factor: 4.280

8.  Adolescent Δ(9)-Tetrahydrocannabinol Exposure Alters WIN55,212-2 Self-Administration in Adult Rats.

Authors:  Maria Scherma; Christian Dessì; Anna Lisa Muntoni; Salvatore Lecca; Valentina Satta; Antonio Luchicchi; Marco Pistis; Leigh V Panlilio; Liana Fattore; Steven R Goldberg; Walter Fratta; Paola Fadda
Journal:  Neuropsychopharmacology       Date:  2015-09-21       Impact factor: 7.853

9.  Individual and additive effects of the CNR1 and FAAH genes on brain response to marijuana cues.

Authors:  Francesca M Filbey; Joseph P Schacht; Ursula S Myers; Robert S Chavez; Kent E Hutchison
Journal:  Neuropsychopharmacology       Date:  2009-12-09       Impact factor: 7.853

Review 10.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.